enVVeno Medical Corp
NASDAQ:NVNO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (9.3), the stock would be worth $-4.53 (143% downside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -21.5 | $10.5 |
0%
|
| 3-Year Average | 9.3 | $-4.53 |
-143%
|
| 5-Year Average | 6.9 | $-3.36 |
-132%
|
| Industry Average | 1.9 | $-0.93 |
-109%
|
| Country Average | 1.5 | $-0.73 |
-107%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
enVVeno Medical Corp
NASDAQ:NVNO
|
6.9m USD | -21.5 | -0.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.6B USD | 11 | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
155.4B USD | 2.1 | 24.8 | |
| US |
|
Stryker Corp
NYSE:SYK
|
112.7B USD | 2.9 | 34.7 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
102.7B USD | 1.5 | 22.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
83.8B USD | 2.3 | 23.5 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.8B USD | 4.9 | 44.5 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 1.2 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.2B USD | 14.9 | 42.7 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.5B USD | 1.2 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
29.9B USD | 4.2 | 20.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.9 |
| Median | 1.5 |
| 70th Percentile | 2.9 |
| Max | 566 432.7 |
Other Multiples
enVVeno Medical Corp
Glance View
enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 24 full-time employees. The company went IPO on 2018-05-31. The firm is focused on improving the standard of care in the treatment of venous disease. The firm is focused on developing tissue-based solutions that are designed for patients with chronic venous insufficiency (CVI). Its lead product, VenoValve, is a porcine based device being developed to surgically implanted in the deep venous system of the leg to treat severe CVI, including the potential to heal recurring venous leg ulcers. The VenoValve is designed to be implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. In addition to the VenoValve, the Company is focused on the development of a second device, enVVe, for the treatment of venous disease.
